Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients

• Glavni autori: Elena M. Tosca (Autor), Elisa Borella (Autor), Chiara Piana (Autor), Salim Bouchene (Autor), Giuseppe Merlino (Autor), Alessio Fiascarelli (Autor), Paolo Mazzei (Autor), Paolo Magni (Autor)
• Format: Knjiga
• Izdano: Wiley, 2023-11-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Abstract MEN1611 is a novel orally bioavailable PI3K inhibitor currently in clinical development for patients with HER2‐positive (HER2+) PI3KCA mutated advanced/metastatic breast cancer (BC) in combination with trastuzumab (TZB). In this work, a translational model‐based approach to determine the mi...